Ram Selvaraju


Valeant Pharmaceuticals Intl Inc (VRX): Tampa Resolution to Pave the Way for FDA Approvals

H.C. Wainwright Is Looking Ahead to Ophthalmology Product Approvals as Tampa Facility Issues Addressed

Protalix Biotherapeutics Inc Fabry Disease Pivotal Program Shows Encouraging Potential: Rodman & Renshaw

Protalix Biotherapeutics Inc (NYSEMKT:PLX) investors are getting skittish today, sending shares on a roughly 5% …

Ocular Therapeutix Inc (OCUL) Gets A Bullish Vote Following 2Q:17 Update

Ocular Therapeutix Inc (NASDAQ:OCUL) shares are on a roughly 4% dip today after the biotech …

H.C. Wainwright Takes Ocular Therapeutix Inc’s (OCUL) Restructuring Plan in Bullish Stride as Shares Dip 5%

Ocular Therapeutix Inc (NASDAQ:OCUL) shares are sliding almost 5% today on the heels of the …

Rodman & Renshaw Roots for Synergy Pharmaceuticals Inc. (SGYP) Ahead of Promising Commercial Trajectory for Trulance

Last week, Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) excited investors with the news that its drug Trulance, …

Synergy Pharmaceuticals Inc (SGYP) Gains Upper Hand in IBS-C Arena

Believing Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) odds in the IBS-C competitive arena just got better, Rodman …

Rodman & Renshaw’s Ram Selvaraju Confident on Synergy Pharmaceuticals Inc (SGYP) Following SNDA Submission

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares are rising almost 3% today after the biotech firm made …

Rodman & Renshaw Cuts Price Target on Valeant Pharmaceuticals Intl Inc (VRX) as Revenue Attrition Will Yield a Significant Impace

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares are sinking almost 5% following the release of financial …